PHF6 (G-9): sc-271767



The Power to Question

BACKGROUND

Zinc finger proteins contain DNA-binding domains and have a wide variety of functions, most of which encompass some form of transcriptional activation or repression. PHF6 (PHD finger protein 6), also known as BORJ, is a 365 amino acid protein that localizes to the nucleus and contains 2 PHD-type zinc fingers. Expressed ubiquitously, PHF6 exists as two alternatively spliced isoforms and is thought to play a role in transcriptional regulation. Upon DNA damage, PHF6 is subject to phosphorylation, probably by ATM or ATR. Mutations in the gene encoding PHF6 are the cause of Boerjeson-Forssman-Lehmann syndrome (BFLS), an X-linked recessive disorder that is characterized by mental retardation, epilepsy, hypogonadism, hypometabolism, obesity with marked gynecomastia, swelling of subcutaneous tissue of the face and narrow palpebral fissure.

REFERENCES

- Borjeson, M., et al. 1962. An X-linked, recessively inherited syndrome characterized by grave mental deficiency, epilepsy, and endocrine disorder. Acta Med. Scand. 171: 13-21.
- 2. Lower, K.M., et al. 2002. Mutations in PHF6 are associated with Börjeson-Forssman-Lehmann syndrome. Nat. Genet. 32: 661-665.
- Lower, K.M., et al. 2004. 1024C>T (R342X) is a recurrent PHF6 mutation also found in the original Borjeson-Forssman-Lehmann syndrome family. Eur. J. Hum. Genet. 12: 787-789.
- Vallée, D., et al. 2004. A novel PHF6 mutation results in enhanced exon skipping and mild Börjeson-Forssman-Lehmann syndrome. J. Med. Genet. 41: 778-783.
- 5. Crawford, J., et al. 2006. Mutation screening in Borjeson-Forssman-Lehmann syndrome: identification of a novel *de novo* PHF6 mutation in a female patient. J. Med. Genet. 43: 238-243.
- 6. Vo s, A.K., et al. 2007. Protein and gene expression analysis of PHF6, the gene mutated in the Börjeson-Forssman-Lehmann syndrome of intellectual disability and obesity. Gene Expr. Patterns 7: 858-871.

CHROMOSOMAL LOCATION

Genetic locus: PHF6 (human) mapping to Xq26.2; Phf6 (mouse) mapping to X A5.

SOURCE

PHF6 (G-9) is a mouse monoclonal antibody raised against synthetic PHF6 peptide of human origin.

PRODUCT

Each vial contains 200 $\mu g \; lg G_1$ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

HF6 (G-9) is recommended for detection of PHF6 of mouse, rat and human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2 μg per 100-500 μg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for PHF6 siRNA (h): sc-90882, PHF6 siRNA (m): sc-152219, PHF6 shRNA Plasmid (h): sc-90882-SH, PHF6 shRNA Plasmid (m): sc-152219-SH, PHF6 shRNA (h) Lentiviral Particles: sc-90882-V and PHF6 shRNA (m) Lentiviral Particles: sc-152219-V.


Molecular Weight of PHF6 isoforms: 41/35 kDa.

Positive Controls: NIH/3T3 whole cell lysate: sc-2210, C6 whole cell lysate: sc-364373 or Neuro-2A whole cell lysate: sc-364185.


RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use m-lgG κ BP-FITC: sc-516140 or m-lgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850.

DATA







PHF6 (G-9): sc-271767. Immunofluorescence staining of formalin-fixed Hep G2 cells showing nucleolar and nuclear localization.

SELECT PRODUCT CITATIONS

- 1. Park, H.J., et al. 2018. 3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk. Nat. Genet. 50: 783-789.
- Chu, Y., et al. 2019. Nudt21 regulates the alternative polyadenylation of Pak1 and is predictive in the prognosis of glioblastoma patients. Oncogene 38: 4154-4168.

RESEARCH USE

For research use only, not for use in diagnostic procedures.